Study: Insulin lispro premixed insulin analogs may be more cost-effective Type 2 diabetes treatment

SAN DIEGO — An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.

The company conducted a study comparing the cost-effectiveness of LAIA, insulin lispro mix 75/25 and insulin lispro mix 50/50 in patients with Type 2 diabetes. Lilly sells insulin lispro under the brand name Humalog.

Analysis of the study found that for patients who do not experience frequent hypoglycemia, insulin lispro premixed insulin analogs are likely to be more cost-effective than LAIA in the long-term treatment of the disease.